Mostrar el registro sencillo del ítem
dc.contributor.author | Matamala, Nerea | |
dc.contributor.author | Vargas, Maria Teresa | |
dc.contributor.author | González-Cámpora, Ricardo | |
dc.contributor.author | Arias, Jose Ignacio | |
dc.contributor.author | Menéndez, Primitiva | |
dc.contributor.author | Andrés-León, Eduardo | |
dc.contributor.author | Yanowsky, Kira | |
dc.contributor.author | Llaneza-Folgueras, Ana | |
dc.contributor.author | Miñambres, Rebeca | |
dc.contributor.author | Martinez-Delgado, Beatriz | |
dc.contributor.author | Benitez, Javier | |
dc.date.accessioned | 2020-04-17T16:14:46Z | |
dc.date.available | 2020-04-17T16:14:46Z | |
dc.date.issued | 2016-04-12 | |
dc.identifier.citation | Oncotarget. 2016 Apr 12;7(15):20068-79. | es_ES |
dc.identifier.issn | 1949-2553 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9617 | |
dc.description.abstract | Emerging evidence suggests that BRCA1 pathway contributes to the behavior of sporadic triple negative breast cancer (TNBC), but little is known about the mechanisms underlying this association. Considering the central role that microRNAs (miRNAs) play in gene expression regulation, the aim of this study was to identify miRNAs specifically deregulated in TNBC and investigate their involvement in BRCA1 regulation. Using locked nucleic acid (LNA)-based microarrays, expression levels of 1919 miRNAs were measured in paraffin-embedded tissues from 122 breast tumors and 11 healthy breast tissue samples. Differential miRNA expression was explored among the main subtypes of breast cancer, and 105 miRNAs were identified as specific for triple negative tumors. In silico prediction revealed that miR-498 and miR-187-5p target BRCA1, and these results were confirmed by luciferase reporter assay. While miR-187-5p was found overexpressed in a luminal B cell line, miR-498 was highly expressed in a triple negative cell line, Hs578T, and its expression was negatively correlated with the levels of BRCA1. We functionally demonstrated that miR-498 inhibits BRCA1 in breast cancer cell lines, and showed that inhibition of miR-498 led to reduced proliferation in the triple negative cell line Hs578T. Our results indicate that miR-498 regulates BRCA1 expression in breast cancer and its overexpression could contribute to the pathogenesis of sporadic TNBC via BRCA1 downregulation. | es_ES |
dc.description.sponsorship | We thank all members of the Human Cancer Genetics Programme of the Spanish National Cancer Research Centre for all their support. We want to particularly acknowledge the patients, the INCLIVA BioBank (PT13/0010/0004) integrated in the Spanish National Biobanks Network, and Pablo Isidro Marrón, coordinator of Biobanco del Principado de Asturias, for their collaboration. This work has been funded by grants from the Spanish Ministry of Economy and Competitiveness (INNPRONTA LIFE project) and FIS PI11/01059 (BM-D). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Impact Journals | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | BRCA1 | es_ES |
dc.subject | microRNA | es_ES |
dc.subject | triple negative breast cancer | es_ES |
dc.subject.mesh | Apoptosis | es_ES |
dc.subject.mesh | BRCA1 Protein | es_ES |
dc.subject.mesh | Biomarkers, Tumor | es_ES |
dc.subject.mesh | Case-Control Studies | es_ES |
dc.subject.mesh | Cell Proliferation | es_ES |
dc.subject.mesh | Cells, Cultured | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | MicroRNAs | es_ES |
dc.subject.mesh | Triple Negative Breast Neoplasms | es_ES |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | es_ES |
dc.title | MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 26933805 | es_ES |
dc.format.volume | 7 | es_ES |
dc.format.number | 15 | es_ES |
dc.format.page | 20068-79 | es_ES |
dc.identifier.doi | 10.18632/oncotarget.7705 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1949-2553 | es_ES |
dc.relation.publisherversion | https://doi.org/10.18632/oncotarget.7705 | es_ES |
dc.identifier.journal | Oncotarget | es_ES |
dc.repisalud.centro | ISCIII::Instituto de Investigación de Enfermedades Raras | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/FIS PI11/01059 | es_ES |
dc.rights.accessRights | open access | es_ES |